PURPOSE: The purpose of this study was to determine the quality of life (QOL) and symptom burden (SB) among breast cancer patients. METHODS: Patients with DCIS, early stage, locally advanced, or metastatic breast cancer completed the Edmonton Symptom Assessment System (ESAS) and the Functional Assessment of Cancer Therapy for Breast Cancer (FACT-B). Patients were divided into subsequent cohorts based on their last day of treatment, age at enrollment, radiation, chemotherapy, and hormone therapy. RESULTS: A total of 1513 patients were enrolled. Metastatic patients had a lower QOL and greatest SB compared to all other patient groups. Patients ≤50 years old with early stage or locally advanced breast cancer had a lower QOL and greater SB for fatigue, depression, and anxiety compared to all other age cohorts. Patients with early stage breast cancer who received chemotherapy had a lower QOL and greater SB. Patients taking selective estrogen receptor modulator (SERM) had greater SB for depression and lower QOL compared to those not on SERM. Patients 2-10 years post-treatment had a lower QOL compared to patients ≥10 years post-treatment. CONCLUSION: Patients ≤50 years old, 2-10 years post-treatment, treated with chemotherapy or SERM had increased SB and decreased QOL. Individualized interventions and programs can be developed to tailor to physical, educational, and psychosocial needs identified across the breast cancer continuum.
PURPOSE: The purpose of this study was to determine the quality of life (QOL) and symptom burden (SB) among breast cancerpatients. METHODS:Patients with DCIS, early stage, locally advanced, or metastatic breast cancer completed the Edmonton Symptom Assessment System (ESAS) and the Functional Assessment of Cancer Therapy for Breast Cancer (FACT-B). Patients were divided into subsequent cohorts based on their last day of treatment, age at enrollment, radiation, chemotherapy, and hormone therapy. RESULTS: A total of 1513 patients were enrolled. Metastatic patients had a lower QOL and greatest SB compared to all other patient groups. Patients ≤50 years old with early stage or locally advanced breast cancer had a lower QOL and greater SB for fatigue, depression, and anxiety compared to all other age cohorts. Patients with early stage breast cancer who received chemotherapy had a lower QOL and greater SB. Patients taking selective estrogen receptor modulator (SERM) had greater SB for depression and lower QOL compared to those not on SERM. Patients 2-10 years post-treatment had a lower QOL compared to patients ≥10 years post-treatment. CONCLUSION:Patients ≤50 years old, 2-10 years post-treatment, treated with chemotherapy or SERM had increased SB and decreased QOL. Individualized interventions and programs can be developed to tailor to physical, educational, and psychosocial needs identified across the breast cancer continuum.
Entities:
Keywords:
Breast cancer; ESAS; FACT-B; Quality of life; Symptom burden
Authors: M J Brady; D F Cella; F Mo; A E Bonomi; D S Tulsky; S R Lloyd; S Deasy; M Cobleigh; G Shiomoto Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: Martine M Goedendorp; Michael A Andrykowski; Kristine A Donovan; Heather S Jim; Kristin M Phillips; Brent J Small; Christine Laronga; Paul B Jacobsen Journal: Cancer Date: 2011-11-15 Impact factor: 6.860
Authors: David Hui; Omar Shamieh; Carlos Eduardo Paiva; Pedro Emilio Perez-Cruz; Jung Hye Kwon; Mary Ann Muckaden; Minjeong Park; Sriram Yennu; Jung Hun Kang; Eduardo Bruera Journal: Cancer Date: 2015-06-08 Impact factor: 6.860
Authors: L Cohen; J Hamer; C Helwig; K Fergus; A Kiss; R Mandel; B Dawson; A Landsberg; K Shein; N Kay; E Warner Journal: Curr Oncol Date: 2016-04-13 Impact factor: 3.677
Authors: Heather S L Jim; Kristin M Phillips; Sari Chait; Leigh Anne Faul; Mihaela A Popa; Yun-Hsiang Lee; Mallory G Hussin; Paul B Jacobsen; Brent J Small Journal: J Clin Oncol Date: 2012-08-27 Impact factor: 44.544
Authors: Danielle B Tometich; Catherine E Mosher; Adam T Hirsh; Kevin L Rand; Shelley A Johns; Marianne S Matthias; Samantha D Outcalt; Bryan P Schneider; Lida Mina; Anna Maria V Storniolo; Erin V Newton; Kathy D Miller Journal: Support Care Cancer Date: 2018-05-07 Impact factor: 3.603
Authors: Yuan-Yuan Lei; Suzanne C Ho; Thomas K H Lau; Carol Kwok; Ashley Cheng; Ka Li Cheung; Roselle Lee; Winnie Yeo Journal: Qual Life Res Date: 2021-01-14 Impact factor: 4.147
Authors: Christine S Ritchie; Fengmin Zhao; Kanan Patel; Judith Manola; Elizabeth A Kvale; Claire F Snyder; Michael J Fisch Journal: Cancer Date: 2017-06-13 Impact factor: 6.860